PortfoliosLab logo
Singular Genomics Systems, Inc. (OMIC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US82933R1005

CUSIP

82933R100

IPO Date

May 27, 2021

Highlights

Market Cap

$50.77M

EPS (TTM)

-$34.68

Total Revenue (TTM)

$1.14M

Gross Profit (TTM)

-$479.00K

EBITDA (TTM)

-$34.01M

Year Range

$5.34 - $23.41

Target Price

$12.45

Short %

2.47%

Short Ratio

4.34

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Singular Genomics Systems, Inc.

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period


OMIC

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of OMIC, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20252.01%0.96%2.99%
20249.78%12.87%-9.82%-21.98%-8.98%-22.83%-1.78%-14.37%120.47%-15.00%64.41%-11.28%40.80%
202333.08%-19.63%-43.72%-18.18%6.57%-21.33%-4.46%-40.73%-18.94%-12.60%17.72%17.35%-77.11%
2022-32.96%6.19%-23.33%-35.18%-20.54%17.54%-0.26%-29.92%-6.37%6.40%-23.31%-1.47%-82.61%
2021-1.35%1.78%-34.32%-8.42%-32.30%23.77%-17.55%1.23%-57.76%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of OMIC is 68, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of OMIC is 6868
Overall Rank
The Sharpe Ratio Rank of OMIC is 5656
Sharpe Ratio Rank
The Sortino Ratio Rank of OMIC is 8484
Sortino Ratio Rank
The Omega Ratio Rank of OMIC is 8181
Omega Ratio Rank
The Calmar Ratio Rank of OMIC is 6262
Calmar Ratio Rank
The Martin Ratio Rank of OMIC is 5858
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Singular Genomics Systems, Inc. (OMIC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Singular Genomics Systems, Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Singular Genomics Systems, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Singular Genomics Systems, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Singular Genomics Systems, Inc. was 99.40%, occurring on Sep 12, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.4%Jun 2, 2021826Sep 12, 2024
-1.35%May 28, 20211May 28, 20211Jun 1, 20212
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Singular Genomics Systems, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Singular Genomics Systems, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 14.5% positive surprise.


-8.00-6.00-4.00-2.000.002020AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJuly
-6.72
-7.86
Actual
Estimate

Valuation

The Valuation section provides an overview of how Singular Genomics Systems, Inc. is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for OMIC relative to other companies in the Medical Instruments & Supplies industry. Currently, OMIC has a P/S ratio of 19.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for OMIC in comparison with other companies in the Medical Instruments & Supplies industry. Currently, OMIC has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items